Our findings suggest that signature genes associated with TREM2+ TAMs, including APOE, SPP1, C1QC, C1QB, and C1QA, can potentially serve as biomarkers for liquid biopsies and immunotherapy modulation in ESCC. This evidence concerns the gene SPP1 and esophageal squamous cell carcinoma.